Phase 1 × Breast Neoplasms × Other solid neoplasm × Clear all
NCT06336148 2025-10-15

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Actym Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
NCT05215574 2024-10-10

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
130 enrolled
NCT05311618 2024-04-01

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
71 enrolled
NCT04430842 2023-01-18

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

Phase 1 Completed
15 enrolled
NCT03517488 2022-12-01

DUET-2

Xencor, Inc.

Phase 1 Completed
150 enrolled
NCT00066404 2020-05-13

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
NCT00413075 2015-07-08

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Valerio Therapeutics

Phase 1 Completed
121 enrolled
NCT00413322 2015-07-08

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

Valerio Therapeutics

Phase 1 Completed
35 enrolled
NCT00375245 2014-01-17

Rapamycin With Grapefruit Juice for Advanced Malignancies

University of Chicago

Phase 1 Completed
41 enrolled
NCT00030498 2013-01-16

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
75 enrolled
NCT00020579 2012-03-15

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
75 enrolled